Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 09, 2020 | June 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 09, 2020 · Filed June 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2030-06-09 | Direct | 23,500 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 23,500 · Balance 23,500 F1: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2030-08-06 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F2: The shares subject to the option vest in 48 equal monthly installments beginning on June 8, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-07-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-23 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 862 shares of Pyxis common stock at an exercise price of $66.67 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
F2: The shares subject to the option vest in 48 equal monthly installments beginning on June 8, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F3: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F4: The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 862 shares of Pyxis common stock at an exercise price of $66.67 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2023 Filed Aug 25, 2023 19:34 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerWarrants (right to buy) · Derivative | 5,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001209191-23-047450 · doc4.xml · derivative · entry 4 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-07-29 F4 · price: The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 862 shares of Pyxis common stock at an exercise price of $66.67 per share. F4 · derivative.exercise_date: The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 862 shares of Pyxis common stock at an exercise price of $66.67 per share. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:34 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047450 · doc4.xml · derivative · entry 3 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F3 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F3 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:34 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 34,084 | Not disclosed Strike: $4.59 | Not disclosed |
DisclosureSEC source: 0001209191-23-047450 · doc4.xml · derivative · entry 2 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,084 shares Expires 2030-08-06 F2 · price: The shares subject to the option vest in 48 equal monthly installments beginning on June 8, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on June 8, 2020. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $26.61 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:34 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-047450 · doc4.xml · nonDerivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 18:26 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051947 · doc4.xml · derivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:21 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-20-012030 · doc1.xml · derivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-09 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:32 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001567619-19-013482 · doc1.xml · derivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-13 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 18:54 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001140361-18-028858 · doc1.xml · derivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-13 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:21 UTC | ARDELYX, INC. ARDX · Entity 4972 | PurchaseCommon Stock | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0001140361-18-026883 · doc1.xml · nonDerivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,000 F1 · ownership.nature: The shares are held directly by the Barthold Family Foundation, for which the Reporting Person serves as a Trustee. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 19:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001140361-17-024615 · doc1.xml · derivative · entry 1 RINGOLD GORDON · CIK 0001101713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-07 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.